Galcanezumab for preventing migraine in children

Galcanezumab is in clinical development for the preventative treatment of paediatric patients with episodic or chronic migraine. Migraine is one of the most common neurological conditions in the paediatric population with unique clinical characteristics that can evolve with age. These characteristics can include shorter attacks, different location of pain (bilateral in younger children), and light and sound sensitivity are best inferred by changes in behaviour. Migraine can occur with or without aura. Migraine with aura consists of visual, sensory or other central nervous system symptoms that usually develop gradually lasting for 5 to 20 minutes, and are usually followed by headache. There remains an unmet need for additional preventative treatments that have proven efficacy and safety in children.